00525nas a2200193   4500000000100000000000100001008004100002100001200043700001400055700001300069700001200082700001600094700001200110700001400122245016200136300001200298490000700310022001400317       2017                            d1 aP. Toth1 aM. Danese1 aG. Villa1 aY. Qian1 aA. Beaubrun1 aA. Lira1 aJ. Jansen00aEstimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context  a555-5640 v20  a1369-6998